Brean Capital has come out today with a pair of substantial downgrades. First, it has downgraded VIVUS (VVUS), maker of the obesity drug Qsymia, to a sell, and set the price target at a painful $7 per share. This is a 50% downside from yesterday's $14.32; the stock fell 5% as a result. Brean also downgraded Celsion (CLSN 10.77%) to a sell, placing the price target at an astonishing $1 per share. Celsion is also down over 5% on the news. In this video, Motley Fool health-care analyst David Williamson tells us what was behind these killer downgrades, and whether investors should be worried.
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.